Proteinuria Articles

We report the case of a 72-year-old woman who was diagnosed in 2006 with renal cell cancer (RCC) and had undergone consecutive tumor nephrectomy (clear-cell RCC, Fuhrmann grade II, stage pT3a, R0).

Damage to and loss of glomerular podocytes has been identified as the culprit lesion in progressive kidney diseases. Here, we combine mass spectrometry-based proteomics with mRNA sequencing, bioinformatics, and hypothesis-driven studies to provide a comprehensive and quantitative map of mammalian podocytes that identifies unanticipated signaling pathways.

Klinefelter's syndrome is the most common chromosomal disorder associated with testicular dysfunction and male infertility. Those affected by Klinefelter's syndrome are at increased risk of systemic lupus erythematosus, breast cancer, non-Hodgkin's lymphoma, and lung cancer.

Diagnosing immune checkpoint inhibitor (ICI)-associated nephritis can be challenging since it is a rare complication of therapy, associated with a spectrum of immune-mediated pathologies, and can present months after ICI therapy discontinuation (i.

To provide a contemporary understanding of chronic kidney disease (CKD) and its relevance to kidney cancer surgery. To resolve points of discrepancy regarding the survival benefits of partial nephrectomy (PN) vs radical nephrectomy (RN) by critically evaluating the results of prospective and retrospective studies in the urologic literature.

To assess the impact of proteinuria on postoperative renal function after open partial nephrectomy (OPN) in patients with a solitary kidney and analyze predictive factors for developing chronic kidney disease (CKD) stage IV or higher.

Although commonly staged according to glomerular filtration rate (GFR), an international workgroup recommended classification of chronic kidney disease (CKD) by cause, GFR, and albuminuria. Data from non-surgical CKD patients indicate proteinuria to be an independent predictor of renal function decline and mortality.

Since angiogenesis plays a key role in tumor growth, progression and metastasization, anti-vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) agents have been developed over the years as anticancer agents, and have changed, for the better, the natural history of a number of cancer types.

The incidence of kidney cancer has been increasing steadily and, until recently, there was a substantial lack of effective therapies for a cancer that is now among the 10 most common cancers in men and women.

Patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors are at a risk of developing proteinuria. Renin-angiotensin system (RAS) inhibitors exert renoprotective effects and might reduce proteinuria risk in these patients.